Showing results (281-290 of 920) with videos related to

Sort By:
Pageof 92
Metabolism: Clinical and Experimental|February 1, 1992
Short-term energy balance in patients with infections: carbohydrate-based versus fat-based dietsB Schneeweiss, W Graninger, P Ferenci, et al.
Acta Radiologica. Supplementum|January 1, 1986
Blood brain barrier modification and chemotherapy. Interventional neuroradiology in the treatment of malignant gliomasK Heimberger, P Samec, H Binder, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised studyM F Gnant, G Blijham, A Reiner, et al.
Journal of Thrombosis and Haemostasis : JTH|November 6, 2009
High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)R Simanek, R Vormittag, C Ay, et al.
Onkologie|October 1, 1989
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancerH Hausmaninger, M Lehnert, G Steger, et al.
Anti-Cancer Drugs|March 27, 2002
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factorCatharina Wenzel, Gottfried J Locker, Manuela Schmidinger, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2021
Tissue distribution of epirubicin after severe extravasation in humansJakob Nedomansky, Werner Haslik, Ursula Pluschnig, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphomaC Marosi, R Heinz, G Steger, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancerH Hausmaninger, M Lehnert, G Steger, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administrationG G Steger, R M Mader, M P Djavanmard, et al.
Pageof 92